Abbvie Inc ABBV:NYSE

Last Price$141.85NYSE Closing Price as of 7:00PM ET 8/19/22
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change+0.56(0.40%)
Bid (Size)$141.01 (1)
Ask (Size)$141.85 (5)
Day Low / High$141.46 - 143.36
Volume4.5 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/19/2022


Abbvie Inc ( NYSE )

Price: $141.85
Change: +0.56 (0.40%)
Volume: 4.5 M
7:00PM ET 8/19/2022

Merck & Co Inc ( NYSE )

Price: $92.07
Change: +0.67 (0.73%)
Volume: 8.8 M
4:00PM ET 8/19/2022

Pfizer Inc ( NYSE )

Price: $49.16
Change: +0.58 (1.19%)
Volume: 15.3 M
4:00PM ET 8/19/2022

Eli Lilly and Co ( NYSE )

Price: $322.77
Change: +6.05 (1.91%)
Volume: 3.4 M
7:00PM ET 8/19/2022

Bristol-Myers Squibb Co ( NYSE )

Price: $75.33
Change: +1.18 (1.59%)
Volume: 7.9 M
7:00PM ET 8/19/2022

Read more news Recent News

I-Mab Partner AbbVie Discontinues Early-Stage Study of Cancer Treatment; Companies Amend Collaboration; Shares Fall
11:25AM ET 8/17/2022 MT Newswires

I-Mab (IMAB) said Tuesday its collaboration partner AbbVie (ABBV) is discontinuing a phase 1b study of lemzoparlimab in combination with azacitidine and...

AbbVie's Allergan Aesthetics Gets FDA Approval for Gel to Improve Jawline Definition
10:07AM ET 8/03/2022 MT Newswires

AbbVie's (ABBV) Allergan Aesthetics unit said Wednesday the US Food and Drug Administration approved its Juvederm Volux XC injectable gel to improve...

--Goldman Sachs Adjusts AbbVie's Price Target to $137 from $141, Keeps Neutral Rating
1:40PM ET 8/01/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AbbVie's Neutral Rating Maintained at Goldman Even as Skyrizi Sales Jump
1:02PM ET 8/01/2022 MT Newswires

AbbVie's (ABBV) neutral rating at Goldman Sachs was maintained despite Q2 sales of plaque psoriasis drug Skyrizi significantly outperforming the firm's...

View all Commentary and Analysis

AbbVie Vs. Pfizer: Impact Of The Inflation Reduction Act On Their Future
5:48PM ET 8/19/2022 Seeking Alpha

The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar
2:40AM ET 8/19/2022 Zacks

JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar are included in this Analyst...

How Will The Inflation Reduction Act Impact The Market?
5:09PM ET 8/16/2022 Seeking Alpha

AbbVie: Outstanding Portfolio Performance Continues
3:52PM ET 8/15/2022 Seeking Alpha

Company Profile

Business DescriptionAbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. View company web site for more details
Address1 North Waukegan Road
North Chicago, Illinois 60064-6400
Number of Employees30,000
Recent SEC Filing08/04/202210-Q
Chairman & Chief Executive OfficerRichard A. Gonzalez
Vice Chairman & PresidentRobert A. Michael
Executive Vice President-OperationsAzita Saleki-Gerhardt
Chief Financial Officer & Senior Vice PresidentScott T. Reents

Company Highlights

Price Open$141.78
Previous Close$141.29
52 Week Range$105.56 - 175.91
Market Capitalization$250.8 B
Shares Outstanding1.8 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.41 / 3.99%
Dividend Ex-Date07/14/2022
Dividend Pay-Date08/15/2022
Dividend Yield 5 Year Average4.08%
Next Earnings Announcement11/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings20.20
Earnings per Share$9.05
Beta vs. S&P 500N/A
Revenue$32.8 B
Net Profit Margin21.90%
Return on Equity83.89%

Analyst Ratings as of 08/17/2022

Consensus RecommendationConsensus Icon
Powered by Factset